QLT ends enrolment for natural history study in patients with RP and LCA

Canadian-based biotechnology company QLT has completed enrolment in its natural history study in subjects with Inherited Retinal Disease (IRD), phenotypically diagnosed with Retinitis Pigmentosa (RP), or Leber Congenital Amaurosis (LCA), due to under…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news